Transaction · 0000950170-25-036712

Bedrosian Camille L

Bedrosian Camille L, CMO, reported a transaction classified as grant at Amylyx Pharmaceuticals, Inc. involving 68420.000000 shares for an estimated $0.00. Reported holdings after the transaction were 206800.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACMO
AMLXAmylyx Pharmaceuticals, Inc.
Filing timeMar 11
Trade dateMar 06, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

AMLX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
AMLX since 2025-03-11Filed 541 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0000950170-25-036712
Common Stock
Transaction date
Mar 06, 2025
Filed Mar 11, 2025, 12:32 AM · 5d delay
Shares
68.4k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
206k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Holdings Increase
-16score
Filing-only score

-16

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on Mar…

  2. F2

    25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's…

Original filing · 0000950170-25-036712
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

AMLX